Use of Long-acting Bupivacaine In Lower Extremity Amputation
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this investigator-initiated study is to assess the use of liposomal
bupivacaine in major extremity amputation and its effects on post-operative opioid narcotic
use, length of stay, and in-hospital costs. Liposomal bupivacaine is an encapsulated,
injectable amide anesthetic intended for use in long-acting local anesthesia. It has been
shown in randomized trials to be effective in reducing post-operative pain while reducing
opioid narcotic use and length of hospital stay following several surgical procedures,
particularly after total knee arthroplasty. Extremity amputation is a painful operation often
performed in seriously ill or debilitated patients, often related to infection, trauma or
malignancy. Application of liposomal bupivacaine in extremity amputation is not well
described. The investigators intend to enroll adults greater than age 18 years of age who are
to undergo major extremity amputation. Patients will receive targeted injections of liposomal
bupivacaine during their procedure. Patient pain scores, total opioid use, and length of
hospital stay will be tracked. Patients receiving liposomal bupivicaine will be compared to
similarly matched subjects who received standard anesthesia regimens without liposomal
bupivicaine. The investigators hypothesize that liposomal bupivicaine used during major
amputation decreases opioid use, hospital stay, and in-hospital costs.